Europe readies revolutionary drug discovery pact

A revolutionary €2 billion deal to spur drug discovery work in Europe is about to be unveiled, according to a new report in the Financial Times. The initiative, known as the Innovative Medicines Initiative, will provide billions of dollars in support for advancing testing of drug safety and efficacy over seven years. For Europe, the IMI marks a concerted attempt to show it can compete with the U.S. as well as Asia in the growing field of drug development work. The European biopharma industry has long been hampered by an anaemic flow of venture funds and governments well known for keeping their purse strings drawn tight when it comes to paying for drugs. The IMI is expected to help rejuvenate the field.

- read the report in the Financial Times

Related Articles:
Group: EU should double research spending. Report
The EU's tips for a successful biotech sector. Report
The trouble with Europe. Editorial

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.